Dr. Shah on the Rationale for Tandem Receptor CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Video

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Nirav N. Shah, MD, associate professor​, Medical College of Wisconsin, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma (NHL).

A single-arm, open-label, phase 1 expansion trial (NCT03019055) evaluated the safety and feasibility of anti-CD20 and anti-CD19 CAR T-cell therapy in patients with relapsed/refractory CD19/CD20​-positive B-cell malignancies, Shah says.

Currently, the majority of available CAR T-cell therapies in B-cell malignancies target CD19, explains Shah. However, CD20 has been a mainstay target in NHL for many years. For example, rituximab (Rituxan), a CD20-directed monoclonal antibody, is a widely utilized therapy in B-cell NHL. As such, dual-targeting CAR T-cell therapies have the potential to engage the tumor at CD19 and CD20 and minimize the risk of antigen escape by CD19 downregulation. Antigen escape is a known mechanism of resistance to single-target CAR T-cell therapy, Shah concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.